View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 3, 2021

Qiagen obtains CE mark for QuantiFeron SARS-CoV-2 assay

The QuantiFeron SARS-CoV-2 assay can detect T-cell response to Covid-19 early in the course of infection or after vaccination.

Qiagen has obtained CE mark for its QuantiFeron SARS-CoV-2 assay, which can assess T-cell responses to Covid-19.

Developed using the company’s QuantiFERON interferon gamma release technology, the SARS-CoV-2 assay is designed to detect interferon-γ (IFN-γ) produced by CD4+ and CD8+ T cells in response to a SARS-CoV-2 peptide cocktail in the blood.

The new in vitro diagnostic test has the ability to detect T-cell responses to Covid-19 early in the course of infection or after vaccination.

Qiagen noted that serology tests that measure antibodies in people after vaccination, often generate positive test results but cannot assess cellular responses.

T-cell detection can provide vital insights into the immune response to a SARS-CoV-2 infection in individuals, which is beyond serology alone.

The new CE mark-granted test from Qiagen can also assess cell-mediated immunity in individuals who have been vaccinated.

Qiagen molecular diagnostics business area head and senior vice-president Jean-Pascal Viola said: “T-cells provide valuable insights into our immune system’s response to Covid-19.

“The more we know about this epidemic, the better equipped the world will be to address this threat that will stay with us.”

The company stated that T-cell response to the virus decreases slowly when compared to the antibody response.

The response helps to indicate how severe the illness triggered by SARS-CoV-2 will be in Covid-19 patients.

It also helps to find the immunity levels in recovered patients.

Furthermore, the new QuantiFERON SARS-CoV-2 assay should be used in combination with other laboratory testing and epidemiological/clinical evaluation.

Recently, the company’s Liaison QuantiFeron-TB Gold Plus assay received approval from the US Food and Drug Administration (FDA) for use on DiaSorin’s Liaison XS platform.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Medical Device Network